Based on what. Wild guess?? They just beat earnings by 8 cebts and all the analysts upgraded their 2013 and 2014 earnings projections. They have just really introduced a new drug and have a deep pipeline. They have a 20% growth rate and the average forward PE with 2014 estimate is only 20X. This stock just based on growth rate could trade minimum 50% higher than it does today without doing anything extraordinary.
rgchjr you got to be kidding .They have a great pipeline and are making money hand over fist. There is only a couple of biotechs in the universe on the same playing field. Please short it I'll bet you end up broke on that bet.
Sentiment: Strong Buy